Partial lipodystrophy (PL) is a rare disease characterized by selective loss of subcutaneous fat. To evaluate changes in apolipoproteins, hepatokines, hormones, appetite regulators, and inflammatory m Show more
Partial lipodystrophy (PL) is a rare disease characterized by selective loss of subcutaneous fat. To evaluate changes in apolipoproteins, hepatokines, hormones, appetite regulators, and inflammatory markers in patients with PL treated with leptin, assess postprandial metabolism and 24-hour dynamics, and identify predictors of hepatic and metabolic response to therapy. We studied 19 subjects from our previous clinical study (NCT01679197), which investigated the effect of leptin on metabolic dysfunction-associated steatohepatitis associated with PL. A mixed-meal test was performed in a subgroup of 14 patients, and paired 24-hour frequent sampling with standardized meals was completed in 5 individuals. Leptin treatment led to reductions in apolipoproteins B, CII, CIII, and E ( Leptin therapy modulates lipid metabolism, postprandial glucose regulation, and appetite signaling in patients with PL, with responses associated with metabolic parameters and carbohydrate intake. Show less